GlassScriptPhysician profile
Suven Shankar
NPI 1760605372
$3,240.30
in general payments reported to CMS, 2019-2025
14 companies · $13.99 in 2025
The $13.99 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2021: $122 · 2022: $602 · 2023: $61.25 · 2024: $1,324 · 2025: $13.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,000 · Food and Beverage: $393 · Travel and Lodging: $6.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,000.00 |
| Food and Beverage | $392.89 |
| Travel and Lodging | $6.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,471.39 | 2019-2024 | |
| Stryker Corporation | $750.00 | 2019 | |
| Boston Scientific Corporation | $225.00 | 2021-2024 | Spyglass Discover |
| Medtronic, INC. | $145.11 | 2022 | |
| Ethicon US, LLC | $138.01 | 2019-2023 | Monocryl |
| Baxter Healthcare | $110.04 | 2022 | |
| Incyte Corporation | $99.95 | 2022 | |
| Allergan, INC. | $98.88 | 2022 | |
| Olympus America INC. | $67.13 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $55.44 | 2019 | |
| Abbvie INC. | $36.18 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $15.30 | 2024 | Lynparza, Keytruda |
| Novartis Pharmaceuticals Corporation | $14.77 | 2024 | |
| Seagen INC. | $13.10 | 2023 | Tukysa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suven Shankar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.